Deal-making has been tepid in India this year, as the economic slowdown and a decline in the rupee-currency hurt sentiment broadly. Investment bankers hope 2014 will be better, especially if the economy starts picking up.

According to Grant Thornton, a U.S.-based consultancy, M&A deal value from January through November 2013 was down 61% to $1.3 billion compared with$3.38 billion in the same period a year earlier.

Here's a look at some of the $1 billion-plus deals in India in 2013.

Apollo-Cooper

This wasn’t the largest deal involving an Indian company in 2013, but it was the most notable because of the boldness of the buyer.

Earlier in the year, drug-maker GlaxoSmithKline PLC, had increased its stake in its consumer-goods unit in India. GlaxoSmithKline paid around $900 million to raise its stake in GlaxoSmithKline Consumer Healthcare India.

In May, Qatar Foundation Endowment, an investment firm that manages some money for the country's royal family, said it would buy a 5% stake in Indian telecom major Bharti Airtel Ltd. for $1.26 billion.

In February, Pennsylvania-based drugmaker Mylan Inc. said it will buy Agila Specialties Pvt., a Bangalore-based maker of generic injectable products.

The deal ended up costing Mylan $1.75 billion it said earlier this month, including a $250 million payment to be made to the Indian seller, Strides Arcolab, if certain regulatory conditions are met, according to a press release.